Mirum Pharmaceuticals (NASDAQ: MIRM) reports results for Sept. 30 2025 quarter

Rhea-AI Filing Summary

Mirum Pharmaceuticals, Inc. furnished a press release that provides a corporate update and announces its financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference into this report. The company also specifies that this information is being furnished, not filed, which limits how it is treated under securities laws and how it may be incorporated into other regulatory documents.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false000175942500017594252025-11-042025-11-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

____________________________________________________

FORM 8-K

____________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 4, 2025

____________________________________________________

Mirum Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

____________________________________________________

Delaware			001-38981			83-1281555
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)
989 East Hillsdale Boulevard Suite 300
Foster City, California						94404
(Address of Principal Executive Offices)						(Zip Code)

Registrant’s Telephone Number, Including Area Code: (650) 667-4085

N/A

(Former Name or Former Address, if Changed Since Last Report)

____________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.0001 per share

MIRM

Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 4, 2025, Mirum Pharmaceuticals, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.

Exhibit No.						Description
99.1						Press Release dated November 4, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			Mirum Pharmaceuticals, Inc.
Date: November 4, 2025			By:			/s/ Christopher Peetz
						Christopher Peetz
						Chief Executive Officer

FAQ

What did Mirum Pharmaceuticals (MIRM) disclose in this SEC report?

Mirum Pharmaceuticals disclosed that it issued a press release providing a corporate update and announcing its financial results for the quarter ended September 30, 2025, furnished as Exhibit 99.1.

Which period do the Mirum Pharmaceuticals (MIRM) results cover?

The financial results discussed by Mirum Pharmaceuticals cover the quarter ended September 30, 2025.

How did Mirum Pharmaceuticals provide its Q3 2025 financial information to investors?

The company provided its quarterly financial information and corporate update through a press release that is attached to the report as Exhibit 99.1.

Is the Mirum Pharmaceuticals press release considered filed or furnished?

The company states that the information in this report, including Exhibit 99.1, is being furnished, not filed, under the Securities Exchange Act of 1934.

Where can investors find the detailed Mirum Pharmaceuticals (MIRM) quarterly numbers?

Detailed financial figures and additional information are contained in the press release referenced as Exhibit 99.1 to the report.

What exhibit is included with Mirum Pharmaceuticals’ current report?

The report includes Exhibit 99.1, which is the press release dated November 4, 2025, and an Inline XBRL cover page data file identified as Exhibit 104.